RetroSPECT: Gallium-67 As a Long-Lived Imaging Agent for Theranostics

Overview

Journal Asia Ocean J Nucl Med Biol

Specialty Nuclear Medicine

Date 2021 Jan 4

PMID 33392343

Citations 4

Authors

Dale L Bailey

Dhanusha Sabanathan

Alireza Aslani

Douglas H Campbell

Bradley J Walsh

Nigel A Lengkeek

Affiliations

Soon will be listed here.

Abstract

A limitation to the wider introduction of personalised dosimetry in theranostics is the relative paucity of imaging radionuclides with suitable physical and chemical properties to be paired with a long-lived therapeutic partner. As most of the beta-emitting therapeutic radionuclides emit gamma radiation as well they could potentially be used as the imaging radionuclide as well as the therapeutic radionuclide. However, the downsides are that the beta radiation will deliver a significant radiation dose as part of the treatment planning procedure, and the gamma radiation branching ratio is often quite low. Gallium-67 has been in use in nuclear medicine for over 50 years. However, the tremendous interest in gallium imaging in theranostics in recent times has focused on the PET radionuclide gallium-68. In this article it is suggested that the longer-lived gallium-67, which has desirable characteristics for imaging with the gamma camera and a suitably long half-life to match biological timescales for drug uptake and turnover, has been overlooked, in particular, for treatment planning with radionuclide therapy. Gallium-67 could also allow non-PET facilities to participate in theranostic imaging prior to treatment or for monitoring response after therapy. Gallium-67 could play a niche role in the future development of personalised medicine with theranostics.

Citing Articles

Chemistry of Antimony in Radiopharmaceutical Development: Unlocking the Theranostic Potential of Sb Isotopes.

Grundmane A, Radchenko V, Ramogida C Chempluschem. 2024; 89(12):e202400250.

PMID: 39048512 PMC: 11639648. DOI: 10.1002/cplu.202400250.

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.

Sharma S, Pandey M Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895931 PMC: 10610335. DOI: 10.3390/ph16101460.

Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer.

Lankoff A, Czerwinska M, Kruszewski M Molecules. 2023; 28(10).

PMID: 37241862 PMC: 10223532. DOI: 10.3390/molecules28104122.

Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers.

Sabanathan D, Campbell D, Velonas V, Wissmueller S, Mazure H, Trifunovic M Asia Ocean J Nucl Med Biol. 2021; 9(2):86-100.

PMID: 34250138 PMC: 8255523. DOI: 10.22038/AOJNMB.2021.55600.1386.

References

Zweit J, Sharma H, Downey S . Production of gallium-66, a short-lived, positron emitting radionuclide. Int J Rad Appl Instrum A. 1987; 38(7):499-501. DOI: 10.1016/0883-2889(87)90194-8. View

Sundberg M, Meares C, Goodwin D, Diamanti C . Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem. 1974; 17(12):1304-7. DOI: 10.1021/jm00258a015. View

Scasnar V, van Lier J . The use of SEP-PAK SI cartridges for the preparation of gallium chloride from the citrate solution. Eur J Nucl Med. 1993; 20(3):273. DOI: 10.1007/BF00170012. View

Edwards C, Hayes R . Tumor scanning with 67Ga citrate. J Nucl Med. 1969; 10(2):103-5. View

Toriihara A, Daisaki H, Yamaguchi A, Yoshida K, Isogai J, Tateishi U . Applying standardized uptake values in gallium-67-citrate single-photon emission computed tomography/computed tomography studies and their correlation with blood test results in representative organs. Nucl Med Commun. 2018; 39(8):720-724. DOI: 10.1097/MNM.0000000000000868. View

Spang P, Herrmann C, Roesch F . Bifunctional Gallium-68 Chelators: Past, Present, and Future. Semin Nucl Med. 2016; 46(5):373-94. DOI: 10.1053/j.semnuclmed.2016.04.003. View

Yeh M, Tse B, Fletcher N, Houston Z, Lund M, Volpert M . Targeted beta therapy of prostate cancer with Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1). EJNMMI Res. 2020; 10(1):46. PMC: 7206480. DOI: 10.1186/s13550-020-00637-x. View

Langbein T, Weber W, Eiber M . Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019; 60(Suppl 2):13S-19S. DOI: 10.2967/jnumed.118.220566. View

Othman M, Verger E, Costa I, Tanapirakgul M, Cooper M, Imberti C . In vitro cytotoxicity of Auger electron-emitting [Ga]Ga-trastuzumab. Nucl Med Biol. 2020; 80-81:57-64. PMC: 7099941. DOI: 10.1016/j.nucmedbio.2019.12.004. View

10.

Scheinberg D, Strand M, Gansow O . Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982; 215(4539):1511-3. DOI: 10.1126/science.7199757. View

11.

Hnatowich D, Layne W, Childs R, Lanteigne D, Davis M, Griffin T . Radioactive labeling of antibody: a simple and efficient method. Science. 1983; 220(4597):613-5. DOI: 10.1126/science.6836304. View

12.

. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of Radioactive Substances Advisory Committee. Nucl Med Commun. 2000; 21 Suppl:S1-93. View

13.

Siegel J, Thomas S, STUBBS J, Stabin M, Hays M, Koral K . MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2):37S-61S. View

14.

van Berkel S, van Delft F . Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov Today Technol. 2018; 30:3-10. DOI: 10.1016/j.ddtec.2018.09.005. View

15.

Morais M, Ma M . Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals. Drug Discov Today Technol. 2018; 30:91-104. PMC: 6291455. DOI: 10.1016/j.ddtec.2018.10.002. View

16.

Bailey D, Hennessy T, Willowson K, Henry E, Chan D, Aslani A . In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging. EJNMMI Phys. 2015; 2(1):20. PMC: 4573647. DOI: 10.1186/s40658-015-0123-2. View

17.

Alley S, Benjamin D, Jeffrey S, Okeley N, Meyer D, Sanderson R . Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008; 19(3):759-65. DOI: 10.1021/bc7004329. View

18.

Cutler C, Hennkens H, Sisay N, Huclier-Markai S, Jurisson S . Radiometals for combined imaging and therapy. Chem Rev. 2012; 113(2):858-83. DOI: 10.1021/cr3003104. View

19.

HERTZ S, Roberts A . Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 2010; 131:81-6. DOI: 10.1001/jama.1946.02870190005002. View

20.

Brandt M, Cardinale J, Aulsebrook M, Gasser G, Mindt T . An Overview of PET Radiochemistry, Part 2: Radiometals. J Nucl Med. 2018; 59(10):1500-1506. DOI: 10.2967/jnumed.117.190801. View